Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study-Reference-Cited by-同舟云学术

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study

Published:2017-09-19 Issue:2 Volume:107 Page:185-193
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Takahashi Naoto^ORCID, ,Tauchi Tetsuzo,Kitamura Kunio,Miyamura Koichi,Saburi Yoshio,Hatta Yoshihiro,Miyata Yasuhiko,Kobayashi Shinichi,Usuki Kensuke,Matsumura Itaru,Minami Yosuke,Usui Noriko,Fukuda Tetsuya,Takada Satoru,Ishikawa Maho,Fujimaki Katsumichi,Gomyo Hiroshi,Sasaki Osamu,Ohishi Kohshi,Miyake Takaaki,Imai Kiyotoshi,Suzushima Hitoshi,Mitsui Hideki,Togitani Kazuto,Kiguchi Toru,Atsuta Yoshiko,Ohtake Shigeki,Ohnishi Kazunori,Kobayashi Yukio,Kiyoi Hitoshi,Miyazaki Yasushi,Naoe Tomoki

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-017-2334-x/fulltext.html

Reference39 articles.

1. Garcia-Manero G, Faderl S, O’Brien S, Cortes J, Talpaz M, Kantarjian HM. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer. 2003;98(3):437–57.

2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54(1):8–29.

3. Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, et al. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther. 2004;4(1):85–96.